Anavex Life Sciences Corp (AVXL)

[TempePhil]

Lilly donanemab versus A273 comparison. Graphically shown below!

From Lilly's PR, "Specifically, at 76 weeks compared to baseline, treatment with donanemab slowed decline by 32 percent compared to placebo as measured by the iADRS, which was statistically significant. "

Slowed decline by 32 percent compared to placebo, means it still declined 68%.
Compare this to Anavex's, peer reviewed "..Analysis of the blarcamesine (ANAVEX2-73) Phase 2a clinical study", figure 2b, where all high dose patients declined 1 ADCS-ADL point, versus the low/medium dose (assumed to be at least placebo or no dose) of -25 points at 148 weeks.
High dose patients declined 4% of what the low/medium dose patients declined.
Or as Lilly's PR would say, for high dose patients, A2-73 SLOWED declined by 96%!
Plotting Lilly's donandmab result, 68% decline (68% of 25 is 17), on the Anavex Figure 2b.


In the donanemab arm, 30.5 percent of patients discontinued treatment due to an adverse event and half of these discontinuations were due to ARIA-related events.
Microhemorrhages (7.6 percent) and superficial siderosis of central nervous system (13.7 percent), nausea (10.7 percent), and infusion-related reaction (IRR) (7.6 percent).
Superficial hemosiderosis of the central nervous system is a disease of the brain resulting from chronic iron deposition in neuronal tissues associated with cerebrospinal fluid.
A2-73 is administered as a pill, while donanemab is delivered by IV (from which 7.6% of patients discontinued because of infusion-related reaction!
The siderosis is definitely not good, and the infusion-related reaction of 7.6% seems suprisingly high.

There is a clear winner, A2-73.